LLY

784.34

0.88% -6.90

시간 외 거래: 783.04 -1.30 -0.17%

일라이 릴리 (LLY)

개요 뉴스 가격 이력 옵션 체인 Financials LLY 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$791.24

열려 있는:

$789.95

하루 거래량:

1.99M

Relative Volume:

0.51

시가총액:

$724.64B

수익:

$49.00B

순이익/손실:

$11.11B

주가수익비율:

63.82

EPS:

12.29

순현금흐름:

$-1.27B

1주 성능:

-3.01%

1개월 성능:

+3.55%

6개월 성능:

+2.56%

1년 성능:

-12.02%

1일 변동 폭

$779.44

$790.62

1주일 범위

$779.44

$825.00

52주 변동 폭

$677.09

$972.53

일라이 릴리 Stock (LLY) Company Profile

명칭

Lilly Eli Co

부문

Healthcare (1178)

산업

Drug Manufacturers - General (19)

전화

(317) 276-2000

주소

LILLY CORPORATE CTR, INDIANAPOLIS, IN

직원

47,000

트위터

@LillyPad

다음 수익 날짜

2024-10-30

최신 SEC 제출 서류

LLY's Discussions on Twitter

LLY을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
LLY Lilly Eli Co	784.34	724.64B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	150.80	376.43B	89.33B	21.81B	18.57B	8.99
NVO Novo Nordisk Adr	74.02	352.49B	43.59B	15.04B	10.74B	3.3766
ABBV Abbvie Inc	185.49	334.73B	57.37B	4.20B	15.39B	2.35
NVS Novartis Ag Adr	116.00	234.21B	53.22B	12.86B	14.85B	6.39

일라이 릴리 Stock (LLY) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-06-05	다운그레이드	Erste Group	Buy → Hold
2025-04-28	다운그레이드	HSBC Securities	Buy → Reduce
2025-04-22	개시	Cantor Fitzgerald	Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-10-17	개시	Bernstein	Outperform
2024-09-13	재개	Citigroup	Buy
2024-08-12	업그레이드	Deutsche Bank	Hold → Buy
2024-02-21	다운그레이드	DZ Bank	Buy → Hold
2024-02-16	재확인	Morgan Stanley	Overweight
2023-12-21	다운그레이드	Daiwa Securities	Buy → Outperform
2023-11-09	개시	Deutsche Bank	Hold
2023-10-20	재개	UBS	Buy
2023-08-09	업그레이드	Jefferies	Hold → Buy
2023-07-26	재확인	Citigroup	Buy
2023-07-14	개시	HSBC Securities	Buy
2023-05-24	재확인	BofA Securities	Buy
2023-05-24	재확인	UBS	Buy
2023-03-13	업그레이드	Wells Fargo	Equal Weight → Overweight
2023-03-06	개시	Jefferies	Hold
2023-02-15	다운그레이드	Societe Generale	Hold → Sell
2022-11-18	개시	Credit Suisse	Outperform
2022-09-22	업그레이드	UBS	Neutral → Buy
2022-05-23	개시	SVB Leerink	Outperform
2022-04-06	재개	Morgan Stanley	Overweight
2022-03-10	개시	Daiwa Securities	Outperform
2022-01-21	업그레이드	DZ Bank	Hold → Buy
2022-01-03	재확인	Bernstein	Mkt Perform
2021-12-17	개시	Goldman	Neutral
2021-12-16	재확인	BMO Capital Markets	Outperform
2021-12-16	재확인	BofA Securities	Buy
2021-12-09	재개	Wells Fargo	Equal Weight
2021-11-19	개시	BMO Capital Markets	Outperform
2021-10-11	업그레이드	Berenberg	Hold → Buy
2021-09-29	업그레이드	Citigroup	Neutral → Buy
2021-08-05	업그레이드	DZ Bank	Hold → Buy
2021-07-27	재개	Truist	Buy
2021-06-24	재확인	Cantor Fitzgerald	Overweight
2021-01-19	업그레이드	Mizuho	Neutral → Buy
2020-12-10	업그레이드	Wolfe Research	Peer Perform → Outperform
2020-11-10	재개	Bernstein	Mkt Perform
2020-09-29	개시	Berenberg	Hold
2020-09-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-06-16	업그레이드	Guggenheim	Neutral → Buy
2020-04-21	다운그레이드	UBS	Buy → Neutral
2020-04-09	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-02-06	개시	Mizuho	Neutral
2019-12-18	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2019-10-17	재개	BofA/Merrill	Buy
2019-05-28	개시	Goldman	Buy
2019-04-24	업그레이드	Edward Jones	Hold → Buy
2019-04-11	다운그레이드	Guggenheim	Buy → Neutral
2019-03-12	개시	JP Morgan	Overweight
2019-01-23	개시	UBS	Buy
2018-11-26	다운그레이드	Citigroup	Buy → Neutral
2018-10-31	업그레이드	Credit Suisse	Underperform → Neutral
2018-10-09	개시	Guggenheim	Buy
2018-10-01	재확인	SunTrust	Buy
2018-09-26	재개	JP Morgan	Overweight

모두보기

일라이 릴리 주식(LLY)의 최신 뉴스

03:06 AM

Eli Lilly’s SWOT analysis: stock poised for growth amid challenges in GLP-1 market - Investing.com

03:06 AM

02:04 AM

Eli Lilly genetic medicine acquisition to address cardiovascular risk - European Pharmaceutical Review

02:04 AM

01:59 AM

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

01:59 AM

01:13 AM

Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks

01:13 AM

11:02 AM

Eli Lilly (LLY): Bariatric Surgery Outperforms GLP-1 Drugs in We - GuruFocus

11:02 AM

10:47 AM

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga

10:47 AM

10:16 AM

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - The Globe and Mail

10:16 AM

09:46 AM

Eli Lilly Stock Dips (18 Jun): Analyzing the Drop and What Traders Should Do Next - Daily Chhattisgarh News

09:46 AM

09:24 AM

UBS reiterates buy rating on Eli Lilly stock following Verve acquisition - Investing.com

09:24 AM

09:06 AM

Eli Lilly stock price target maintained at $1,100 by Bernstein on Verve deal - Investing.com Canada

09:06 AM

08:56 AM

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug - Messenger-Inquirer

08:56 AM

08:06 AM

Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers

08:06 AM

07:19 AM

Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition - PMLiVE

07:19 AM

05:45 AM

Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus

05:45 AM

05:38 AM

Eli Lilly acquisition of Verve signals renewed interest in gene editing - Investing.com

05:38 AM

Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com

05:38 AM

03:38 AM

Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play - Insider Monkey

03:38 AM

Jun 17, 2025

In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech

Jun 17, 2025

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com

Jun 17, 2025

Eli Lilly to buy gene-editing biotech Verve for $1.3 billion - The Boston Globe

Jun 17, 2025

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com

Jun 17, 2025

Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology

Jun 17, 2025

Eli Lilly (LLY) 5-Year Growth Surges Over 383%, Showcasing Enduring Strength Beyond Daily Market Moves - Daily Chhattisgarh News

Jun 17, 2025

Eli Lilly LLY (NYSE:LLY) Expands Biotech Reach With Verve Deal Talks Dow Jones Industrial Average - Kalkine Media

Jun 17, 2025

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN

Jun 17, 2025

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - MSN

Jun 17, 2025

UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy - Insider Monkey

Jun 17, 2025

Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize

Jun 17, 2025

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView

Jun 17, 2025

Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize

Jun 17, 2025

Lilly acquires cardiovascular genetic medicine company for up to $1.3B - Inside INdiana Business

Jun 17, 2025

Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B - Cardiovascular Business

Jun 17, 2025

Lilly to acquire Verve in $1B bet on gene editing for heart disease - BioPharma Dive

Jun 17, 2025

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - MSN

Jun 17, 2025

Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion - Bloomberg

Jun 17, 2025

Liking what it sees, Lilly to buy base editing partner Verve for $1.3B - FirstWord Pharma

Jun 17, 2025

Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters

Jun 17, 2025

Eli Lilly Stock Dives Today: A Trader’s Analysis of Key LLY Metrics - Daily Chhattisgarh News

Jun 17, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - Mint

Jun 17, 2025

Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News

Jun 17, 2025

Eli Lilly acquires biotech company for USD 1.3bn - medwatch.com

Jun 17, 2025

Lilly to buy gene-editing partner Verve for up to US$1.3 billion in cardiac care push - CP24

Jun 17, 2025

Verve soars after Eli Lilly announces $1.3 billion acquisition of gene-editing company - Sherwood News

Jun 17, 2025

Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine News

Jun 17, 2025

Lilly spends $1B on Boston biotech developing gene-editing cholesterol drug - The Business Journals

Jun 17, 2025

Eli Lilly to acquire Verve Therapeutics for USD 1.3 billion - Medical Dialogues

Jun 17, 2025

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition - Benzinga

Jun 17, 2025